A characteristic polypeptide of human PF4 and its application
Through the characteristic peptide and multi-reaction monitoring technology of human PF4, combined with the combined use of liquid chromatography and mass spectrometry, the accuracy and cost problems of detection of PF4 and heparin-based drug complexes are solved, and the rapid and low-cost detection effect is achieved. It is suitable for Diagnosis and monitoring of HIT.
Patent Information
- Application Number
- CN202211129971.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-16
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-09-16
AI Technical Summary
The prior art is difficult to accurately detect the size and quantity of complexes formed by PF4 and heparin drugs, and the detection cost is high, which affects the diagnosis and monitoring of HIT.
Provide a characteristic polypeptide of human PF4. Through enzymatic lysis and multi-reaction monitoring technology, combined with liquid chromatography and mass spectrometry technology, the complex formed by PF4 and heparin drugs is detected, avoiding the decomposition of the complex in the chromatographic column and reducing the Test costs and equipment requirements.
It realizes rapid and accurate detection of PF4 and heparin-based drug complexes, reduces detection costs, is suitable for large-scale applications, and provides a low-cost immunogenicity evaluation method.
Smart Images

Figure CN115490766B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to a characteristic polypeptide of human PF4 and application thereof. Background Art
[0002] Platelet factor 4 (PF4), also known as chemokine (CX-Cmotif) ligand 4 (CXCL4), belongs to the CXC subfamily of the chemokine superfamily. After being synthesized by bone marrow megakaryocytes, it is stored in α-granules. When platelets are activated by endogenous or exogenous stimuli, PF4 is released from the α-granules of platelets. PF4 in the human body mainly exists as a tetramer, and its monomer has a molecular weight of 7.8 kDa and contains 70 amino acid residues. Like other CXC chemokine subfamily proteins, PF4 contains 4 highly conserved cysteine residues in its amino acid sequence. Lysine residues Lys-61, Lys-62, Lys-65 and Lys-66 of PF4 constitute the main heparin binding domain of PF4, and Arg-20, Arg-22, Lys-46 and Arg-49 synergistically participate in the binding of heparin to PF4. The structural domain composed of four Lys plays a vital role in the biological activity of PF4. The main physiological function of PF4 is to promote blood coagulation. When the human body is injured, platelets are activated and release PF4. The released PF4 repairs the wound by binding to endothelial cells and prevents excessive blood loss. PF4 can also inhibit the heparin-mediated AT III signaling pathway by neutralizing heparin, thereby promoting blood coagulation.
[0003] HIT (heparin-induced thrombocytopenia, HIT) is one of the adverse reactions that may be caused during the use of heparin drugs. It can cause local venous thrombosis and thrombosis, and in severe cases, it can cause death. The mechanism of HIT first involves the interaction between PF4 in the human body and heparin drugs to form a complex; the body produces antibodies to the complex, and the antibodies further bind to the complex to form a multi-molecular immunogen complex. The multi-molecular complex activates platelets and causes platelet aggregation, leading to thrombocytopenia. Therefore, it is of great application value and significance to quickly detect and characterize the size and quantity of the complex produced by PF4 and heparin drugs.
[0004] Size-exclusion chromatography (SEC) is the most commonly used method to characterize the molecular weight and content ratio of each component in a mixture. It is also widely used in the characterization of complexes formed by the interaction between proteins or proteins and small molecules. Size-exclusion chromatography can predict the molecular weight of polymers by establishing a standard curve using standard substances. However, since the molecular weight of the platelet factor 4-heparin complex is too large, there is no suitable standard substance to calibrate its molecular weight, making it difficult to measure accurately and effectively. Moreover, size-exclusion chromatography requires the complex formed by platelet factor 4 and heparin drugs to pass directly through the chromatographic column. The complex may decompose in the chromatographic column, thereby affecting the accuracy of the test results.
[0005] Multi-angle light scattering (MALS) is also a commonly used method for absolute quantification of molecular weight and content. It is a detection method based on static light scattering technology that uses multi-angle light scattering to measure the optical properties of a substance over a wide range of scattering angles to obtain its molecular weight and content. When multi-angle light scattering measures molecular weight, no theoretical assumptions are required, and the measurement results do not depend on standards. It is a direct and absolute measurement method. However, the sample amount required for its detection is generally in the milligram level, the price of platelet factor 4 is relatively high, and the sample making cost is relatively high. Because the detection cost is relatively high in actual applications, it is not suitable for large-scale applications. Summary of the invention
[0006] In view of the problems existing in the prior art, the purpose of the present invention is to provide a characteristic polypeptide of human PF4.
[0007] The characteristic polypeptide of human PF4 has low equipment requirements when used for detecting the complex formed by PF4 and heparin drugs, has fast analysis and detection speed, and low detection cost, and can be used as one of the evaluation methods for the immunogenicity of heparin drugs.
[0008] In order to achieve the above-mentioned object of the invention, the technical solution of the present invention is as follows:
[0009] In a first aspect, the present invention provides a characteristic polypeptide of human PF4, wherein the sequences of the polypeptides are SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively.
[0010] Furthermore, the sequence is SEQ ID NO: 1: VRPRHITSL.
[0011] Furthermore, the sequence is SEQ ID NO: 2: DLQAPL.
[0012] Furthermore, the sequence is SEQ ID NO: 3: KKIIKKLLES.
[0013] Furthermore, the mass-to-charge ratio of the peptide segment of SEQ ID NO: 1 is m / z=360.2; the mass-to-charge ratio of the peptide segment of SEQ ID NO: 2 is m / z=656.4; and the mass-to-charge ratio of the peptide segment of SEQ ID NO: 3 is m / z=400.6.
[0014] In a second aspect, the present invention provides a method for preparing the characteristic polypeptide of human PF4, comprising the following steps:
[0015] Step 1: After resuspending PF4, add formic acid to adjust the pH to 2-3, and add pepsin for enzymatic hydrolysis;
[0016] Step 2: Desalt and enrich the enzymatic solution, vacuum dry it, and store it at low temperature.
[0017] Furthermore, the mass ratio of PF4 to pepsin described in step 1 is 1:1-5; the preferred mass ratio is 1:1.5.
[0018] Furthermore, the enzymatic hydrolysis temperature in step 1 is 20-60°C, preferably 37°C; the enzymatic hydrolysis time is 1-15 min; preferably 10 min.
[0019] Furthermore, the desalting and enriching process described in step 2 includes:
[0020] The packing was activated with 2 column volumes of acetonitrile and then equilibrated with 2 column volumes of formic acid in water. 18 Manual column, the sample to be desalted was loaded twice, and then washed with 2 column volumes of formic acid solution. 18 The column was manually eluted with 2 column volumes of formic acid in 80% acetonitrile.
[0021] Furthermore, the desalting and enrichment process described in step 2 includes: activating the filler with 2 column volumes of acetonitrile, and then balancing the C with 2 column volumes of 0.1% formic acid in water. 18 Manual column, the sample to be desalted was loaded twice, and then washed with 2 column volumes of 0.1% formic acid in water. 18 For manual columns, use 2 column volumes of 0.1% formic acid in 80% acetonitrile to elute. Dry the eluate.
[0022] Furthermore, the storage temperature in step 2 is -10°C to -50°C, preferably -20°C.
[0023] In a third aspect, the present invention provides an application of the characteristic polypeptide of human PF4, which is specifically applied to the analysis and detection of the complex formed by PF4 and heparin drugs, and the detection steps include:
[0024] a: PF4 and heparin drugs were mixed and incubated to form a complex;
[0025] b: Enzymatic hydrolysis of the complex system;
[0026] c: Enrich the enzymatic hydrolysis products and use multiple reaction monitoring technology for sample detection.
[0027] Furthermore, the heparin drugs described in step a are selected from one or more of heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, tingaparin sodium, parparin sodium, certoparin sodium, reviparin sodium, and bemiparin sodium.
[0028] Furthermore, the mixed incubation process described in step a includes:
[0029] PF4 and heparin drugs were mixed at a molar ratio of 2:1, 1:1, 1:2, 1:4 and 1:8, and PBS buffer was added to each mixed system to make up the volume. After mixing evenly, the mixture was incubated at 20-60°C for 0.5-3 h; the preferred condition was incubation at 37°C for 1.0 h.
[0030] Further, the enzymatic hydrolysis process described in step b comprises:
[0031] Formic acid was added to each sample to adjust the pH to 2.0-3.0, and then pepsin was added, with the mass ratio of PF4 to pepsin being 1:1-5. The enzymolysis was carried out at 20-60°C for 1-15 min, and 1 M NaOH was used to neutralize the system to quench the enzymolysis reaction. The optimal conditions were a mass ratio of PF4 to pepsin of 1:1.5, an enzymolysis temperature of 37°C, and an enzymolysis time of 10 min.
[0032] Furthermore, the process of enriching the enzymatic hydrolysis product described in step c comprises:
[0033] The packing was activated with 200 μL of acetonitrile, followed by equilibration with 2 column volumes of 0.1% formic acid in water. 18 Manual column, the sample to be desalted was loaded twice, and then washed with 2 column volumes of 0.1% formic acid in water. 18 Manual column, finally eluted with 2 column volumes of 0.1% formic acid in 80% acetonitrile. Dry the eluate and store at -20°C before mass spectrometry analysis.
[0034] Furthermore, the multiple reaction monitoring technology described in step c specifically uses octadecyl carbon chain bonded silica gel liquid chromatography-mass spectrometry to detect the polypeptides VRPRHITSL, DLQAPL and / or KKIIKKLLES in the enzymatic hydrolysate, and adds 13 C and 15 N isotope-labeled VRPRHITSL[ 13 C6, 15 N]、DLQAPL[ 13 C6, 15 N] and / or K[ 13 C6, 15 N2]KIIKKLLES for absolute quantification.
[0035] Furthermore, the liquid chromatography-mass spectrometry detection conditions in the multiple reaction monitoring technique described in step c are:
[0036] Using Hypersil™ BDS C 18 The separation was performed on a chromatographic column (150 × 2.1 mm) with a flow rate of 0.2 mL / min and an elution gradient as follows (proportions are in volume percentage): 0-3 min 2% mobile phase B, 3-5 min 2%-20% mobile phase B, 5-10 min 20%-35% mobile phase B, 10-13 min 35% mobile phase B, 13.01-20 min 98% mobile phase B, 20.01-27 min 98%-2% mobile phase B;
[0037] A triple quadrupole mass spectrometer was used for quantitative analysis in positive ion mode. The parameters were set as follows: positive ion mode, MRM detection mode, ion source spray voltage of 4500 V, transfer tube temperature of 275°C, sheath gas pressure of 25 arb, backflush gas pressure of 0 arb, auxiliary gas pressure of 0 arb, collision gas pressure of 1.5 arb, ion focus lens voltage of 75, and channel parameters as follows:
[0038]
[0039] Further, the detection form of VRPRHITSL polypeptide ion is [M] 3+ , the mass-to-charge ratio is 360.2, and the product ions are 256.2, 509.3, 323.7, and 219.1.
[0040] The DLQAPL peptide ion detection format is [M] + , the mass-to-charge ratio is 656.4, and the product ions are 229.2, 428.2, 300.2, and 357.2.
[0041] KKIIKKLLES peptide ion detection form is [M] 3+ , the mass-to-charge ratio is 400.6, and the product ions are 106.0, 242.2, and 370.3.
[0042] The isotope-labeled peptide of VRPRHITSL is VRPRHITSL[ 13 C6, 15 N], and the detection form of peptide ions is [M] 3+ , the mass-to-charge ratio is 362.5, and the product ions are 256.2, 509.3, 323.7, and 226.1.
[0043] The isotope-labeled peptide of DLQAPL is DLQAPL[ 13 C6, 15 N], and the peptide ion detection form is [M] + The mass-to-charge ratio is 656.4, and the product ions are 236.2, 428.2, 307.2, and 357.2.
[0044] The isotope-labeled peptide of KKIIKKLLES is K[ 13 C6, 15 N2]KIIKKLLES, peptide ion detection form is [M] 3+ , the mass-to-charge ratio is 403.3, and the product ions are 106.0, 246.2, and 374.3.
[0045] The peptide content obtained from the multiple reaction monitoring can reflect the size and number of complexes formed by PF4 and heparin drugs. The larger and more complexes formed by PF4 and heparin drugs, the fewer peptides VRPRHITSL, DLQAPL and / or KKIIKKLLES detected by the multiple reaction monitoring. As the degree of polymerization of the complex formed by PF4 and heparin drugs gradually increases, the non-heparin drug binding domain peptide DLQAPL will be encapsulated in the complex, so the amount of peptide DLQAPL produced by enzymatic hydrolysis will decrease accordingly; as the number of complexes formed by PF4 and enoxaparin sodium gradually increases, the binding of heparin drug binding domain peptides VPRHITSL and KKIIKKLLES to heparin drugs increases, so the amount of peptides VRPRHISL and KKIIKKLLES produced by enzymatic hydrolysis will decrease accordingly. By comparing the VRPRHITSL, DLQAPL and / or KKIIKKLLES content results obtained after enzymatic hydrolysis of incubation systems with different PF4 / heparin drug ratios, the size and number of complexes formed under different PF4 / heparin drug ratios can be inferred. By comparing the VRPRHITSL, DLQAPL and / or KKIIKKLLES content results obtained after enzymatic hydrolysis of the incubation system of PF4 with different types of heparin drugs at the same PF4 / heparin drug ratio, it can be inferred that the size and number of complexes formed by PF4 and different types of heparin drugs at the same PF4 / heparin drug ratio.
[0046] Compared with the prior art, the present invention has the following effects:
[0047] First, the present invention provides a characteristic polypeptide of human PF4, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, the preparation method of the characteristic polypeptide is simple and easy to obtain. In the analysis and detection of the complex formed by PF4 and heparin drugs, it has the significant advantages of low equipment requirements, fast analysis and detection speed, and low detection cost.
[0048] Secondly, the present invention provides an application method of a human PF4 characteristic polypeptide in the analysis and detection of a complex formed by PF4 and heparin drugs. Compared with the molecular exclusion chromatography, the characteristic polypeptide in the present invention does not need to directly pass the complex formed by PF4 and heparin drugs through the chromatographic column during the application process, thereby avoiding the possibility of changes in the complex in the chromatographic column; compared with the multi-angle light scattering method, the characteristic polypeptide in the present invention only requires micrograms of PF4 during the application process, and the analysis speed is fast and the cost is low. In addition, the detection and analysis method provided by the present invention can use conventional liquid chromatography, high-resolution mass spectrometry, and triple quadrupole mass spectrometry, so that the application method of the present invention can be widely used in scientific research institutes, enterprises, detection institutions, etc., and has strong practicality. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 . Extracted ion chromatograms of VRPRHITSL, DLQAPL, and KKIIKKLLES (m / z = 360.2, z = 3; m / z = 656.4, z = 1; m / z = 400.6, z = 3).
[0050] Figure 2 . High-resolution primary mass spectrum of VRPRHITSL (m / z=360.2, z=3).
[0051] Figure 3 . High-resolution primary mass spectrum of DLQAPL (m / z=656.4, z=1).
[0052] Figure 4 . High-resolution primary mass spectrum of KKIIKKLLES (m / z=400.6, z=3).
[0053] Figure 5 . MS / MS spectrum of VRPRHITSL (m / z=360.2, z=3).
[0054] Figure 6 . MS / MS spectrum of DLQAPL (m / z=656.4, z=1).
[0055] Figure 7 . MS / MS spectrum of KKIIKKLLES (m / z=400.6, z=3).
[0056] Figure 8 . Absolute quantitative results of VRPRHITSL, DLQAPL and KKIIKKLLES at different PF4 / enoxaparin sodium ratios in PBS buffer system.
[0057] Fig. 9 .Absolute quantitative results of VRPRHITSL, DLQAPL and KKIIKKLLES at different PF4 / enoxaparin sodium ratios in plasma system.
[0058] Fig.10 .The absolute quantitative results of VRPRHITSL, DLQAPL and KKIIKKLLES at different PF4 / enoxaparin sodium ratios in the plasma system described in Example 3 and different PF4 / heparin sodium ratios in the plasma system described in Example 4. DETAILED DESCRIPTION
[0059] The present application will be further described in detail below by way of example so that those skilled in the art can practice the present application. It should be understood that other embodiments may be adopted, and appropriate changes may be made without departing from the spirit or scope of the present application. In order to avoid unnecessary details for enabling those skilled in the art to practice the present application, the description may omit certain information known to those skilled in the art. Therefore, the following detailed description should not be understood in a restrictive sense, and the scope of the present invention is defined only by the appended claims. The following examples are convenient for a better understanding of the present application, but are not intended to limit the scope of the present application.
[0060] Embodiment 1
[0061] 1. Sample Preparation
[0062] 1.1 Proteolysis
[0063] Resuspend PF4 in ultrapure water to a concentration of 0.5 μg / μL, take 1.04 μL of PF4 solution, dilute to 30 μL with PBS buffer, and the final concentration is 17.33 ng / μL. Add 12 μL of 20% formic acid to adjust pH = 2.0, then add 0.78 μL of pepsin (1 μg / μL), the mass ratio of protein to enzyme is 1:1.5. Enzyme hydrolysis is carried out at 37 °C for 10 min, and the system is neutralized with 1 M NaOH to quench the enzymatic reaction.
[0064] 1.2 C 18 Manual column desalting and enrichment
[0065] The packing was activated with 200 μL of acetonitrile, followed by equilibration with 2 column volumes of 0.1% formic acid in water. 18 Manual column, the sample to be desalted was loaded twice, and then washed with 2 column volumes of 0.1% formic acid in water. 18 Manual column, finally eluted with 2 column volumes of 0.1% formic acid in 80% acetonitrile solution. Dry the eluate and store at -20℃ before mass spectrometry analysis.
[0066] 2. Liquid chromatography-mass spectrometry technology to detect samples
[0067] 2.1 Preparation of mobile phase
[0068] Mobile phase A was 0.1% formic acid in water;
[0069] Mobile phase B was 0.1% formic acid in acetonitrile;
[0070] 2.2 C 18 -MS / MS analysis
[0071] Thermo Scientific Easy-nLC 1200 liquid chromatograph was used; the pre-column was Acclaim PepMap TM 100 (2 cm × 75 μm, nano Viper 2Pk), the analytical column was Acclaim PepMap TM RSLC (25 cm × 75 μm, nano Viper, C 18 , 2 μm) with a flow rate of 300 nL / min, and the elution gradient was as follows (all proportions are volume percentages): 0-4 min 2%-7% mobile phase B, 4-44 min 7%-22% mobile phase B, 44-54 min 22%-35% mobile phase B, 54-59 min 35%-90% mobile phase B, 59.01-74 min 90% mobile phase B.
[0072] The mass spectrometer model was Orbitrap Fusion Lumos; the mass spectrometer used Orbitrap as the mass analyzer, and the positive ion mode was scanned with a primary scanning range of 200-2000, a primary resolution of 120000, a secondary resolution of 15000, and a primary ion automatic gain control (AGC) setting of 4×10 5 , secondary 5×10 4 , fragmented by high energy collision-induced dissociation (HCD) with the collision energy set to 30%.
[0073] 3. Data processing
[0074] Figure 1-Figure 7 C 18 -MS / MS data processing results. The results of pepsin hydrolysis of PF4 were simulated using the PeptideMass function provided by Uniport. 18 -MS / MS results, the sequences of the characteristic peptides of PF4 were obtained, which were VRPRHITSL, DLQAPL, KKIIKKLLES, and the extracted ion chromatograms were shown in Figure 1 As shown. In the enzymatic hydrolysis product data analysis, the VRPRHITSL ion m / z=360.2 can be detected (such as Figure 2 ) and its resulting fragment ions (such as Figure 5 DLQAPL ions m / z=656.4 can also be detected (as shown in Figure 3 ) and its resulting fragment ions (such as Figure 6 ); the ion m / z=400.6 of KKIIKKLLES can also be detected (as shown in Figure 4 ) and its resulting fragment ions (such as Figure 7The above data results qualitatively characterized the characteristic peptides of PF4, indicating that the preparation method can obtain the characteristic peptides of PF4, VRPRHITSL, DLQAPL, and KKIIKKLLES.
[0075] Embodiment 2
[0076] 1. Sample Preparation
[0077] 1.1 Complex formation
[0078] 1.04 μL of 0.5 μg / μL PF4 was mixed with 1.5 μL, 3.0 μL, 6.0 μL, 12.0 μL and 24.0 μL of 0.1 μg / μL enoxaparin sodium, that is, the molar ratios of PF4 to enoxaparin sodium were 2:1, 1:1, 1:2, 1:4 and 1:8. 27.46 μL, 25.96 μL, 22.96 μL, 16.96 μL and 4.96 μL of PBS buffer were added to the mixed system, mixed well and incubated at 37°C for 1.0 h.
[0079] 1.2 Pepsin hydrolysis
[0080] 12 μL of 20% formic acid was added to each sample to adjust the pH to 2.0, and then 0.78 μL of 1 μg / μL pepsin was added, with a protein to enzyme ratio of 1:1.5. The enzymatic reaction was performed at 37 °C for 10 min, and 1 M NaOH was used to neutralize the system to quench the enzymatic reaction.
[0081] 1.3 Addition of isotope-labeled peptide internal standard
[0082] Isotope-labeled peptides of known amounts of VRPRHITSL, DLQAPL, and KKIIKKLLES were added as quantitative internal standards, and 100 ng of VRPRHITSL[ 13 C6, 15 N], 60 ng DLQAPL[ 13 C6, 15 N], 120 ng K[ 13 C6, 15 N2]KIIKKLLES.
[0083] 1.4 C 18 Manual column desalting and enrichment
[0084] The packing was activated with 200 μL of acetonitrile, followed by equilibration with 2 column volumes of 0.1% formic acid in water. 18 Manual column, the sample to be desalted was loaded twice, and then washed with 2 column volumes of 0.1% formic acid in water.18 Manual column, finally eluted with 2 column volumes of 0.1% formic acid in 80% acetonitrile. Dry the eluate and store at -20°C before mass spectrometry analysis.
[0085] 2. Multiple reaction monitoring technology to detect samples
[0086] 2.1 Preparation of mobile phase
[0087] Mobile phase A was 0.1% formic acid in water;
[0088] Mobile phase B was 0.1% formic acid in acetonitrile;
[0089] 2.2 C 18 -MRM analysis
[0090] Using Hypersil™ BDS C 18 The separation was performed on a chromatographic column (150 × 2.1 mm) with a flow rate of 0.2 mL / min and an elution gradient as follows (proportions are in volume percentage): 0-3 min 2% mobile phase B, 3-5 min 2%-20% mobile phase B, 5-10 min 20%-35% mobile phase B, 10-13 min 35% mobile phase B, 13.01-20 min 98% mobile phase B, 20.01-27 min 98%-2% mobile phase B;
[0091] A triple quadrupole mass spectrometer was used for quantitative analysis in positive ion mode. The parameters were set as follows: positive ion mode, MRM detection mode, ion source spray voltage of 4500 V, transfer tube temperature of 275°C, sheath gas pressure of 25 arb, backflush gas pressure of 0 arb, auxiliary gas pressure of 0 arb, collision gas pressure of 1.5 arb, ion focus lens voltage of 75, and channel parameters as follows:
[0092] Table 1. MRM transition parameters
[0093]
[0094] Table 2. MRM transition parameters for isotope-labeled peptide internal standards
[0095]
[0096] 3. Data processing
[0097] Figure 8 C 18 -MRM data processing results, using isotope-labeled peptides as internal standards for absolute quantification, and calculating the absolute contents of the three peptides at different ratios.
[0098] Embodiment 3
[0099] 1. Sample Preparation
[0100] 1.1 Complex formation
[0101] 1.04 μL of 0.5 μg / μL PF4 was mixed with 1.5 μL, 3.0 μL, 6.0 μL, 12.0 μL and 24.0 μL of 0.1 μg / μL enoxaparin sodium, that is, the molar ratios of PF4 to enoxaparin sodium were 2:1, 1:1, 1:2, 1:4 and 1:8. 27.46 μL, 25.96 μL, 22.96 μL, 16.96 μL and 4.96 μL of plasma were added to the mixed system, mixed well and incubated at 37 °C for 1.0 h.
[0102] 1.2 Pepsin hydrolysis
[0103] 12 μL of 20% formic acid was added to each sample to adjust the pH to 2.0, and then 0.78 μL of 1 μg / μL pepsin was added, with a protein to enzyme ratio of 1:1.5. The enzymatic reaction was performed at 37 °C for 10 min, and the system was neutralized with 1 M NaOH to quench the enzymatic reaction.
[0104] 1.3 Addition of isotope-labeled peptide internal standard
[0105] Isotope-labeled peptides of known amounts of VRPRHITSL, DLQAPL, and KKIIKKLLES were added as quantitative internal standards, and 100 ng of VRPRHITSL[ 13 C6, 15 N], 60 ng DLQAPL[ 13 C6, 15 N], 120 ng K[ 13 C6, 15 N2]KIIKKLLES.
[0106] 1.4 C 18 Manual column desalting and enrichment
[0107] The packing was activated with 200 μL of acetonitrile, followed by equilibration with 2 column volumes of 0.1% formic acid in water. 18 Manual column, the sample to be desalted was loaded twice, and then washed with 2 column volumes of 0.1% formic acid in water. 18 Manual column, finally eluted with 2 column volumes of 0.1% formic acid in 80% acetonitrile solution. Dry the eluate and store at -20℃ before mass spectrometry analysis.
[0108] 2. Multiple reaction monitoring technology to detect samples
[0109] 2.1 Preparation of mobile phase
[0110] Mobile phase A was 0.1% formic acid in water;
[0111] Mobile phase B was 0.1% formic acid in acetonitrile;
[0112] 2.2 C 18 -MRM analysis
[0113] Using Hypersil™ BDS C 18 The separation was carried out on a chromatographic column (150 × 2.1 mm) with a flow rate of 0.2 mL / min and an elution gradient as follows (all proportions are volume percentages): 0-3 min 2% mobile phase B, 3-5 min 2%-20% mobile phase B, 5-10 min 20%-35% mobile phase B, 10-13 min 35% mobile phase B, 13.01-20 min 98% mobile phase B, 20.01-27 min 98%-2% mobile phase B;
[0114] Quantitative analysis was performed using a triple quadrupole mass spectrometer in positive ion mode, and the parameters were set as follows: positive ion mode, MRM detection mode, ion source spray voltage of 4500 V, transfer tube temperature of 275°C, sheath gas pressure of 25 arb, backflush gas pressure of 0 arb, auxiliary gas pressure of 0 arb, collision gas pressure of 1.5 arb, and ion focusing lens voltage of 75. The MRM channel parameters are the same as those in Example 1.
[0115] 3. Data processing
[0116] Fig. 9 C 18 -MRM data processing results, using isotope-labeled peptides as internal standards for absolute quantification, and calculating the absolute contents of the three peptides at different ratios.
[0117] Embodiment 4
[0118] 1. Sample Preparation
[0119] 1.1 Complex formation
[0120] 1.04 μL of 0.5 μg / μL PF4 was mixed with 0.53 μL, 1.07 μL, 2.13 μL, 4.27 μL and 8.53 μL of 1 μg / μL heparin sodium, respectively, that is, the molar ratio of PF4 to heparin sodium was 2:1, 1:1, 1:2, 1:4 and 1:8. 28.43 μL, 27.89 μL, 26.83 μL, 24.69 μL and 20.43 μL of plasma were added to the mixed system, respectively, mixed well and incubated at 37 °C for 1.0 h.
[0121] 1.2 Pepsin hydrolysis
[0122] 12 μL of 20% formic acid was added to each sample to adjust the pH to 2.0, and then 0.78 μL of 1 μg / μL pepsin was added, with a protein to enzyme ratio of 1:1.5. The enzymatic reaction was performed at 37 °C for 10 min, and the system was neutralized with 1 M NaOH to quench the enzymatic reaction.
[0123] 1.3 Addition of isotope-labeled peptide internal standard
[0124] Isotope-labeled peptides of known amounts of VRPRHITSL, DLQAPL, and KKIIKKLLES were added as quantitative internal standards, and 100 ng of VRPRHITSL[ 13 C6, 15 N], 60 ng DLQAPL[ 13 C6, 15 N], 120 ng K[ 13 C6, 15 N2]KIIKKLLES.
[0125] 1.5 C 18 Manual column desalting and enrichment
[0126] The packing was activated with 200 μL of acetonitrile, followed by equilibration with 2 column volumes of 0.1% formic acid in water. 18 Manual column, the sample to be desalted was loaded twice, and then washed with 2 column volumes of 0.1% formic acid in water. 18 Manual columns were eluted with 2 column volumes of 0.1% formic acid in 80% acetonitrile. The eluate was dried and stored at -20 °C before mass spectrometry analysis.
[0127] 2. Multiple reaction monitoring technology to detect samples
[0128] 2.1 Preparation of mobile phase
[0129] Mobile phase A was 0.1% formic acid in water;
[0130] Mobile phase B was 0.1% formic acid in acetonitrile;
[0131] 2.2 C 18 -MRM analysis
[0132] Using Hypersil™ BDS C 18 The separation was carried out on a chromatographic column (150 × 2.1 mm) with a flow rate of 0.2 mL / min and an elution gradient as follows (all proportions are volume percentages): 0-3 min 2% mobile phase B, 3-5 min 2%-20% mobile phase B, 5-10 min 20%-35% mobile phase B, 10-13 min 35% mobile phase B, 13.01-20 min 98% mobile phase B, 20.01-27 min 98%-2% mobile phase B;
[0133] The quantitative analysis was performed using a triple quadrupole mass spectrometer in positive ion mode with the following parameters: positive ion mode, MRM detection mode, ion source spray voltage of 4500 V, transfer tube temperature of 275 °C, sheath gas pressure of 25 arb, backflush gas pressure of 0 arb, auxiliary gas pressure of 0 arb, collision gas pressure of 1.5 arb, and ion focusing lens voltage of 75.
[0134] The MRM channel parameters are the same as those in Example 1.
[0135] 3. Data processing
[0136] Fig.10 The absolute quantitative results of VRPRHITSL, DLQAPL and KKIIKKLLES at different PF4 / enoxaparin sodium ratios in the plasma system described in Example 3 and different PF4 / heparin sodium ratios in the plasma system described in Example 4. The absolute contents of the three peptides at different ratios were calculated.
[0137] By analyzing the data in Examples 2, 3, and 4, it can be concluded that: 1. As the ratio of PF4 / heparin drugs gradually decreases, the amount of the polypeptide DLQAPL produced by enzymatic hydrolysis decreases accordingly, and thus the degree of polymerization of the complex formed by PF4 and heparin drugs gradually increases; 2. As the ratio of PF4 / heparin drugs gradually decreases, the amounts of the two heparin drug binding domain peptides VRPRHITSL and KKIIKKLLES on PF4 produced by enzymatic hydrolysis also decrease accordingly, and thus the number of complexes formed by PF4 and heparin sodium gradually increases.
[0138] By comparing Example 2 and Example 3, it can be concluded that: 1. PF4 and heparin drugs can form complexes not only in PBS buffer, but also in plasma with a complex environment; 2. The content of polypeptides VRPRHITSL, DLQAPL and KKIIKKLLES in the plasma system at the same ratio is higher, indicating that the complexes formed by PF4 and heparin drugs in plasma are less and smaller. By comparing Example 3 and Example 4, it can be concluded that: 1. The number and size of complexes formed by PF4 with enoxaparin sodium and heparin sodium at different ratios have the same trend, and both increase and increase as the ratio of PF4 / heparin drugs gradually decreases; 2. There are significant differences in the content of polypeptides VRPRHITSL, DLQAPL and KKIIKKLLES at the same ratio using different types of heparin drugs, so when using heparin sodium, the size and number of complexes formed by polypeptides of different heparin drugs at the same ratio are significantly different.
[0139] Therefore, this method can accurately detect the contents of peptides VRPRHITSL, DLQAPL and KKIIKKLLES in different proportions, accurately characterize the number and size of complexes formed by PF4 and heparin drugs, and can also very sensitively distinguish the properties of complexes formed by different heparin drugs.
Claims
1. A characteristic polypeptide combination of human PF4, characterized in that: The characteristic polypeptide combination consists of a sequence of SEQ ID NO: 1, a sequence of SEQ ID NO: 2 and a sequence of SEQ ID NO: 3; The sequence SEQ ID NO: 1: VRPRHITSL; The sequence SEQ ID NO: 2: DLQAPL; The sequence is SEQ ID NO: 3: KKIIKKLLES.
2. An application of the characteristic polypeptide combination of human PF4 according to claim 1, characterized in that: Specifically used in the analysis and detection of the complex formed by PF4 and heparin drugs, the detection steps include: a: PF4 and heparin drugs were mixed and incubated to form a complex; b: After enzymatically hydrolyzing the complex described in step a, adding an isotope-labeled polypeptide internal standard; c: Enrich the enzymatic hydrolysis products and use multiple reaction monitoring technology to detect the samples; The enzymatic hydrolysis in step b is to resuspend PF4, add formic acid to adjust the pH to 2-3, and add pepsin for enzymatic hydrolysis; the enzymatic hydrolysis temperature is 20-60°C; the enzymatic hydrolysis time is 1-15min; The step b of adding an isotope-labeled polypeptide internal standard is to add 13 C and 15 N isotope-labeled VRPRHITSL[ 13 C6, 15 N]、DLQAPL[ 13 C6, 15 N] and / or K[ 13 C6, 15 N2]KIIKKLLES for absolute quantification; The liquid chromatography detection conditions in the multiple reaction monitoring technique described in step c are: Using Hypersil™ BDS C 18 The separation was performed on a 150 × 2.1 mm column with a flow rate of 0.2 mL / min and an elution gradient as follows: 0-3 min 2% mobile phase B, 3-5 min 2%-20% mobile phase B, 5-10 min 20%-35% mobile phase B, 10-13 min 35% mobile phase B, 13.01-20 min 98% mobile phase B, 20.01-27 min 98%-2% mobile phase B; the above percentages are by volume; The mass spectrometry detection conditions in the multiple reaction monitoring technique described in step c are: A triple quadrupole mass spectrometer was used for quantitative analysis in positive ion mode. The parameters were set as follows: positive ion mode, MRM detection mode, ion source spray voltage of 4500 V, transfer tube temperature of 275°C, sheath gas pressure of 25 arb, backflush gas pressure of 0 arb, auxiliary gas pressure of 0 arb, collision gas pressure of 1.5 arb, ion focus lens voltage of 75, and channel parameters as shown in the following table: 。 3. The use according to claim 2, characterized in that: The heparin drugs described in step a are selected from one or more of heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, tingaparin sodium, parparin sodium, certoparin sodium, reviparin sodium, and bemiparin sodium.
